Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?

08:00 EDT 21st March 2020 | BioPortfolio

Summary of "Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: International journal of hematology
ISSN: 1865-3774


DeepDyve research library

PubMed Articles [45719 Associated PubMed Articles listed on BioPortfolio]

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

Treatment goals and ambitions have even been upwardly revised since demonstration was made that under certain conditions, treatment-free remission was possible. Herein, we will discuss on how to try t...

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients ...

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.

Endoscopic and surgical treatment options for chronic pancreatitis: an imaging perspective.

Chronic pancreatitis is a chronic fibro-inflammatory syndrome characterized by chronic pancreatic inflammation leading to fibrosis and scarring. Patients with this multifactorial debilitating illness ...

Oral Implant Treatment for a Patient Undergoing Molecularly Targeted Drug Therapy for Chronic Myelocytic Leukemia: A Case Report.

The primary concern in carrying out dental implant treatment in patients with chronic myelogenous leukemia is the development of peri-implantitis. However, currently, the advent of molecular-targeted ...

Clinical Trials [21653 Associated Clinical Trials listed on BioPortfolio]

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

This trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is ver...

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remiss...

A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib

This is a prospective, single arm, phase II study to assess the effect of nilotinib reduced to half the standard dose for 12 months on treatment-free remission in patients with CML-CP trea...

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment su...

Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP

Thrombopoietin-receptor agonists (Tpo-RAs) have profoundly changed the management of ITP. However, today, there are no international recommendations concerning the long-term use of these c...

Medical and Biotech [MESH] Definitions

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

A treatment technique utilizing play as a medium for expression and communication between patient and therapist.

Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.

A broad category of membrane transport proteins that specifically transport FREE FATTY ACIDS across cellular membranes. They play an important role in LIPID METABOLISM in CELLS that utilize free fatty acids as an energy source.

Therapeutic act or process that initiates a response to a complete or partial remission level.

Quick Search

DeepDyve research library

Searches Linking to this Article